Tyche Industries Ltd
Incorporated in 1998, Tyche Industries Ltd
does manufacturing of active pharmaceutical ingredients[1]
- Market Cap ₹ 145 Cr.
- Current Price ₹ 142
- High / Low ₹ 224 / 129
- Stock P/E 12.0
- Book Value ₹ 133
- Dividend Yield 2.12 %
- ROCE 12.7 %
- ROE 9.42 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.06 times its book value
Cons
- The company has delivered a poor sales growth of -2.34% over past five years.
- Company has a low return on equity of 10.7% over last 3 years.
- Earnings include an other income of Rs.7.66 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
104 | 64 | 54 | 43 | 52 | 54 | 74 | 78 | 62 | 75 | 70 | 65 | 63 | |
94 | 57 | 51 | 37 | 43 | 45 | 52 | 54 | 51 | 59 | 57 | 54 | 52 | |
Operating Profit | 11 | 7 | 3 | 6 | 9 | 9 | 21 | 25 | 11 | 16 | 13 | 11 | 11 |
OPM % | 10% | 11% | 5% | 14% | 18% | 17% | 29% | 32% | 18% | 21% | 18% | 17% | 17% |
0 | 0 | 2 | 2 | 2 | 3 | 4 | 4 | 3 | 5 | 6 | 7 | 8 | |
Interest | 1 | 1 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | -0 | -0 | -0 | 0 |
Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Profit before tax | 8 | 3 | 3 | 6 | 9 | 10 | 23 | 27 | 13 | 19 | 17 | 17 | 16 |
Tax % | 32% | 33% | 4% | 48% | 34% | 27% | 25% | 25% | 26% | 26% | 26% | 26% | |
6 | 2 | 2 | 3 | 6 | 7 | 18 | 20 | 9 | 14 | 12 | 12 | 12 | |
EPS in Rs | 5.39 | 1.88 | 2.41 | 3.00 | 5.72 | 6.98 | 17.13 | 19.49 | 9.10 | 13.82 | 11.94 | 12.11 | 11.80 |
Dividend Payout % | 9% | 26% | 21% | 17% | 9% | 7% | -0% | 5% | 16% | -0% | 21% | 25% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | -2% |
3 Years: | 2% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 20% |
5 Years: | -7% |
3 Years: | 8% |
TTM: | -1% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | -14% |
3 Years: | 1% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 13% |
3 Years: | 11% |
Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 33 | 34 | 35 | 38 | 43 | 50 | 67 | 86 | 94 | 107 | 116 | 126 |
11 | 9 | 11 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | |
19 | 12 | 11 | 13 | 14 | 14 | 18 | 21 | 16 | 20 | 10 | 11 | |
Total Liabilities | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 137 | 137 | 147 |
33 | 29 | 28 | 27 | 20 | 19 | 18 | 18 | 17 | 17 | 18 | 16 | |
CWIP | 0 | 0 | 0 | 0 | -0 | -0 | -0 | 1 | -0 | -0 | -0 | 0 |
Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
40 | 35 | 39 | 34 | 47 | 55 | 77 | 98 | 104 | 120 | 119 | 131 | |
Total Assets | 74 | 64 | 67 | 61 | 67 | 74 | 95 | 117 | 120 | 137 | 137 | 147 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 2 | 12 | 11 | 5 | 4 | 15 | 15 | 4 | 6 | 8 | 9 | |
-6 | -1 | -1 | 1 | 6 | 1 | 2 | 0 | 3 | -3 | 4 | -1 | |
0 | -3 | 2 | -11 | -1 | -0 | -1 | -1 | -1 | -2 | -2 | -3 | |
Net Cash Flow | 3 | -2 | 12 | 1 | 11 | 4 | 17 | 15 | 7 | 2 | 10 | 5 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 46 | 91 | 107 | 81 | 68 | 69 | 64 | 80 | 96 | 107 | 100 | 95 |
Inventory Days | 91 | 138 | 68 | 84 | 85 | 123 | 122 | 148 | 148 | 195 | 157 | 245 |
Days Payable | 68 | 76 | 93 | 130 | 87 | 96 | 91 | 93 | 78 | 134 | 48 | 85 |
Cash Conversion Cycle | 69 | 153 | 82 | 34 | 67 | 96 | 94 | 135 | 167 | 168 | 210 | 255 |
Working Capital Days | 35 | 77 | 21 | 60 | 67 | 87 | 77 | 83 | 121 | 129 | 144 | 151 |
ROCE % | 18% | 7% | 5% | 12% | 18% | 17% | 34% | 32% | 13% | 17% | 14% | 13% |
Documents
Announcements
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015.
11 Sep - ANVISA GMP inspection successfully completed at Kakinada facility during first week of September 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
8 Sep - Appointed Mr. Satya Srinivas Uppalapati as Additional Executive Director effective 05 Sep 2025; subject to 27th AGM approval.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
6 Sep - Newspaper publication, Notice of 27th Annual General Meeting
-
Addendum To Outcome Of Board Meeting In Accordance With The SEBI (LODR) Regulations, 2015 ("Listing Regulations")
6 Sep - Re-appointment of Mrs. Penumatsa Vijaya Lakshmi as Independent Director, five-year term from 30 Sep 2025, subject to shareholder approval.
-
Announcement under Regulation 30 (LODR)-Change in Management
5 Sep - Board approved Sandeep Gokaraju as Chairman‑cum‑MD w.e.f. 05‑Sep‑2025; Ganesh Kumar resigns CMD; AGM Sep 30, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is a manufacturer and exporter of APIs, Intermediates and Nutraceuticals. It is one of the largest Indian manufacturers of Glucosamine Hydrochloride and corresponding sodium and potassium salts which are mainly exported to USA and Europe